Abstract
Results A total of 401 patients with a history of hypersensitivity reaction to RCM and were premedicated at re-exposure to RCM. Male was 177 (44.1%) and mean age was 55.83i¾11.92 years. Most common hypersensitivity symptom was urticaria (259, 64.6%), followed by itching (36.7%), rash (21.4%) and angioedema (13.2%). Hypotension was reported in 9 (2.2%) and syncope 5 (1.2%). Systemic steroid was prescribed in 143 patients (35.4%). After premedication, 139 patients (77.7%) had no hypersensitivity reactions to re-exposed RCM. Incidence of symptom after premedication such as uriticaria (12.4%), itching (5.6%), rash (5.1%), angioedema (2.2%) were significantly decreased compared with previous incidence (P 0.05) Conclusion The use of corticosteroid or antihistamine before administration of RCM may diminish the overall prevalence of reactions. Randomized controlled studies of the effects of pretreatment in patients with hypersensitivity reaction to RCM were needed.
Highlights
For patients with a known history of hypersensitivity reactions to radiocontrast media (RCM), premedication with antihistamines and corticosteroids before receiving RCM is recommended
Incidence of symptom after premedication such as uriticaria (12.4%), itching (5.6%), rash (5.1%), angioedema (2.2%) were significantly decreased compared with previous incidence (P
We investigate the effectiveness of premedication for hypersensitivity reactions to radiocontrast media (RCM) in one tertiary hospital
Summary
For patients with a known history of hypersensitivity reactions to radiocontrast media (RCM), premedication with antihistamines and corticosteroids before receiving RCM is recommended. It has been shown that such premedication decreases the frequency of mild and aggregate allergic like reactions. Premedication does not prevent all subsequent reactions. 139 patients (77.7%) had no hypersensitivity reactions to re-exposed RCM. Incidence of symptom after premedication such as uriticaria (12.4%), itching (5.6%), rash (5.1%), angioedema (2.2%) were significantly decreased compared with previous incidence (P0.05)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
